EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial

Haojie Zhou iD, Minzhi Lv iD, Wei Li, Yan Wang, Jing Wu, Qing Liu, Tianshu Liu iD, Qian Li iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf341 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Haojie Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200030, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Aminoquinolines, Acrylamides, Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Special Clinical Research Program of Shanghai Municipal Health Commission Health Industry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amplification/overexpression of the human epidermal growth factor receptor 2 (HER2) gene drives cell proliferation, differentiation, and migration of breast cancer. However, HER2-targeted therapies are not standard treatment for HER2-positive non-breast solid tumors currently. This phase II open-label basket trial evaluated pyrotinib’s efficacy and safety in patients with non-breast solid tumors.

Methods

Patients with previously treated HER2-positive advanced non-breast solid tumors were enrolled at Zhongshan Hospital, Fudan University. All participants received pyrotinib in 21-day cycles. Primary endpoint was objective response rate (ORR) at 6 weeks, assessed per RECIST version 1.1. Circulating tumor DNA (ctDNA) analysis was conducted to identify biomarkers of efficacy.

Results

Fifty-three patients were enrolled and 51 evaluable for efficacy analysis. The median follow-up was 32.2 months. ORR was 18.9% (95% CI: 10.2%-31.7%) and disease control rate was 73.6% (95% CI: 60.1%-84.2%). Median progression-free survival (mPFS) was 5.1 (95% CI: 4.2-8.1) months and median overall survival (mOS) was 17.2 (95% CI: 16.2-33.2) months. Patients with colorectal cancer had the highest ORR and the longest mOS (33.2 months, 95% CI: 14.9-51.5). Among patients with HER2 overexpression, those with immunohistochemistry 3+ had longer mPFS and mOS. Sixteen patients required dose reductions due to grade 3 adverse events (AEs); no ≥grade 4 AEs occurred. Analysis of ctDNA revealed that patients with progression disease had higher mutation frequency, more diverse mutational profiles, and higher copy number burden.

Conclusion

Pyrotinib demonstrated a favorable safety profile and modest efficacy in patients with previously treated HER2-positive advanced non-breast solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesAminoquinolinesAcrylamidesNeoplasmsHumansFemaleMiddle AgedAgedAdultMaleAged, 80 and over

Stichwörter der Autor:innen

HER2-directed agentsbasket trialcirculating tumor DNApyrotinib

Substanzen

Erb-b2 Receptor Tyrosine KinasesAminoquinolinesAcrylamidespyrotinibERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200030, China.
  • Department of Oncology, Central Hospital of Xuhui District, Shanghai 200030, China.
  • Department of Cancer Prevention and Sreening, Zhongshan Hospital, Fudan University, Shanghai 200030, China.
  • Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai 200030, China.
  • Department of Evidence-Based Medicine, Fudan University, Shanghai 200030, China.
  • Department of Medical Oncology, Shanghai Geriatric Medical Center, Shanghai 201100, China.

ORCID-Profile: Haojie Zhou, Minzhi Lv, Tianshu Liu, Qian Li

Förderung

  • Special Clinical Research Program of Shanghai Municipal Health Commission Health Industry

Zitieren

APA

Zhou, H., Lv, M., Li, W., Wang, Y., Wu, J., Liu, Q., Liu, T., & Li, Q. (2025). Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial. The Oncologist. https://doi.org/10.1093/oncolo/oyaf341

Vancouver

Zhou H, Lv M, Li W, Wang Y, Wu J, Liu Q, et al. Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial. The Oncologist. 2025. doi:10.1093/oncolo/oyaf341

BibTeX
@article{Zhou2025,
  author = {Zhou, Haojie and Lv, Minzhi and Li, Wei and Wang, Yan and Wu, Jing and Liu, Qing and Liu, Tianshu and Li, Qian},
  title = {Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf341}
}
Kostenlos starten →